PubRank

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.

PubWeight™: 2.04‹?› | Rank: Top 2%

🔗 View Article (PMID 26378418)

Published in JAMA Oncol on December 01, 2015

Authors

Sindy Magnan1, Ryan Zarychanski2, Laurie Pilote1, Laurence Bernier1, Michèle Shemilt3, Eric Vigneault4, Vincent Fradet5, Alexis F Turgeon6

Author Affiliations

1: Division of Radiation Oncology, Department of Medicine, CHU de Québec, Université Laval, Québec City, Québec, Canada.
2: Department of Internal Medicine, Sections of Hematology/Medical Oncology and Critical Care, University of Manitoba, Winnipeg, Manitoba, Canada3Department of Haematology and Medical Oncology, Cancercare Manitoba, Winnipeg, Manitoba, Canada.
3: CHU de Québec Research Center, Université Laval, Québec City, Québec, Canada.
4: Division of Radiation Oncology, Department of Medicine, CHU de Québec, Université Laval, Québec City, Québec, Canada4CHU de Québec Research Center, Université Laval, Québec City, Québec, Canada.
5: CHU de Québec Research Center, Université Laval, Québec City, Québec, Canada5Division of Urology, Department of Surgery, CHU de Québec, Université Laval, Québec City, Québec, Canada.
6: CHU de Québec Research Center, Université Laval, Québec City, Québec, Canada6Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, CHU de Québec, Université Laval, Québec City, Québec, Canada.

Articles citing this ↘

A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis (2016) 0.77

Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. J Urol (2015) 0.75

The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. JAMA Oncol (2015) 0.75

Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Curr Treat Options Cardiovasc Med (2017) 0.75